Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Diabetes Diabetes for November/December 2019 Cardiometabolic risk burden is high in patients under 50 with type 2 diabetes, Obesity Ups Type 2 Diabetes Risk Far More Than Lifestyle, Genetics, More must reads Diabetes for September/October 2019 Certain diabetes drugs may thwart dementia, Smoking, inactivity most powerful lifestyle post-MI risk factors, Panel releases guidelines for red meat, processed meat consumption, Machine learning–derived risk score predicts heart failure risk in diabetes patients, DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug, More must readsDiabetes for July/August 2019 Diabetes targets remain elusive for patients, Oral semaglutide monotherapy delivers HbA1c improvements in type 2 diabetes, CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes, CAROLINA findings reaffirm linagliptin’s safety, free glimepiride of CV-risk stigma, More must readsDiabetes for May/June 2019 Do Black Patients with Type 2 Diabetes Gain Cardiac Benefit From SGLT2 and GLP-1 Drugs?, Which antidiabetic for elderly diabetes patients? It depends on their CV risk, GLP-1 RA dulaglutide yields cardiac gains, even in non–at-risk patients, How to reverse T2D with a crash diet, SGLT2 inhibitors prevent HF hospitalization regardless of baseline LVEF, More must readsDiabetes for March/April 2019 Canagliflozin lowers kidney failure risk in T2D: CREDENCE, Dapagliflozin’s cardiovascular benefits bloom in T2D with prior MI, Newer antihyperglycemic drugs have distinctive CV, kidney benefits, Semaglutide plus SGLT2 inhibitors improves glycemic control in type 2 diabetes, More must readsPages1 2 next › last »
